Cite
A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
MLA
Hisashi Tanaka, et al. “A Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer.” BMC Cancer, vol. 17, no. 1, Oct. 2017, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s12885-017-3684-8.
APA
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, & Sadatomo Tasaka. (2017). A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer. BMC Cancer, 17(1), 1–6. https://doi.org/10.1186/s12885-017-3684-8
Chicago
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, et al. 2017. “A Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer.” BMC Cancer 17 (1): 1–6. doi:10.1186/s12885-017-3684-8.